New type 2 diabetes drug helps lower blood sugar: study
But, FDA wants questions about the drug's long-term safety answered before approval
(HealthDay) -- A new type of medication for type 2 diabetes helps to lower blood sugar levels when used in concert with insulin and other diabetes drugs, new research suggests.
The medicine is called dapagliflozin, and average blood sugar levels were lower in those taking the drug compared to those taking a placebo; both groups in the trial also took insulin and other diabetes medications. Daily insulin doses went down for those on the drug, and body weight dropped slightly.
"This study looked at the effects of dapagliflozin treatment in people with type 2 diabetes with high blood sugars despite insulin treatment, and found it was effective at reducing blood sugar, body weight and blood pressure," said study author Dr. John Wilding, head of the department of obesity and endocrinology at the University Hospital Aintree in Liverpool, England.
"Possible disadvantages include a slightly higher risk of urine infections and genital fungal infections, although most of these responded well to standard treatment," he added.
Results of the study are published in the March 20 issue of the Annals of Internal Medicine. The study was funded by AstraZeneca and Bristol-Meyers Squibb, two pharmaceutical companies who are collaborating in the development of dapagliflozin.
Type 2 diabetes affects the way your body metabolizes sugar. In type 2 diabetes, the body either doesn't use the hormone insulin effectively or it doesn't make enough insulin, according to the U.S. National Library of Medicine. Insulin allows the body's cells to convert sugar from food into fuel. If it isn't used well or there's not enough insulin, blood sugar levels will rise. High blood sugar levels can cause a number of serious health consequences, including damage to the eyes, kidneys and blood vessels.
In some cases, type 2 diabetes can be controlled with lifestyle changes, such as losing weight and exercising regularly. However, most people need medications to control their blood sugar levels, and many people need a combination of medications to lower their blood sugar.
Dapagliflozin is from a new class of type 2 diabetes medications that work by blocking the ability of the kidneys to hold sugar. This causes the kidneys to release sugar as waste in the urine.
Numerous clinical trials have found dapagliflozin to be effective at lowering blood sugar levels. Despite this beneficial effect, the U.S. Food and Drug Administration recently decided not to approve dapagliflozin until more information is available about its possible long-term side effects. The most significant concern cited by the FDA was a potential increase in the rates of bladder and breast cancer in people taking the drug.
Although the current trial wasn't long enough to look for longer-term outcomes, such as cancer, Wilding said that the slight increase in bladder and breast cancer was likely a chance finding. But, he said, because there is concern, it's important to continue surveillance for these cancers in future trials.
The current study was designed to see how the drug would work in combination with insulin and other type 2 diabetes medications.
The researchers enrolled just over 800 people with type 2 diabetes who were already taking insulin to control their blood sugar levels. In addition, the study volunteers could be taking up to two more blood sugar-lowering medications.
Study participants were randomly assigned to one of four treatment groups. They received either a placebo, or one of three doses of dapagliflozin (2.5, 5 or 10 milligrams) daily.
After 24 weeks of treatment, people in the dapagliflozin group lowered their average hemoglobin A1C level between 0.79 percent to 0.96 percent compared with a 0.39 percent reduction in those on placebo. Hemoglobin A1C is about a three-month average blood sugar level. People with diabetes are advised to keep their levels below 7 percent.
Insulin use also dropped for people taking the medication, suggesting more effective blood sugar control. And, body weight decreased between 2 pounds and 3.5 pounds for those taking the medication. Weight increased by almost 1 pound for those on placebo, according to the study.
In addition, the researchers found that both systolic and diastolic blood pressure levels went down more for those on the drug compared to those on placebo.
"In this study, dapagliflozin seemed to improve glucose control and lower the need for insulin, as well as cause some weight loss," said Dr. Sue Kirkman, senior vice president of medical affairs and community information of the American Diabetes Association.
"This is an interesting study on a new medication that's under development. It has a novel mechanism of action, but there have been some ongoing concerns about the safety of this class of medications, and none has been approved by the FDA yet," she noted.
More information: Learn more about type 2 diabetes and currently approved treatments from the American Diabetes Association.
Copyright © 2012 HealthDay. All rights reserved.
- FDA questions safety of experimental diabetes drug Jul 15, 2011 | not rated yet | 0
- Brain important in lowering blood sugar Jan 11, 2006 | not rated yet | 0
- FDA approves new diabetes treatment Oct 17, 2006 | not rated yet | 0
- Mothers' high blood sugar in pregnancy is linked to children's reduced insulin sensitivity Jun 22, 2010 | not rated yet | 0
- Some patients may not need insulin for long-term control of type 2 diabetes Jun 15, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Relating physics forces and entropy
1 hour ago Consider proton and electron are seperated in space at some finite distance.Now suppose they released then the decrease in potential energy equals...
Force Between Two Concentric Solenoids
4 hours ago Imagine a finite length solenoid with outer radius R1 and inner radius R2. This solenoid has a time-varying current going though it. This solenoid is...
Synchrotron, question about insertion devices and electron velocity
5 hours ago When an electron enters an insertion device (wiggler and undulator) from the storage ring in a synchrotron the tangential velocity is equal to the...
Equating differentials => equating coefficients
6 hours ago Hi all, In thermodynamics one often has equations like A dx + B dy = ∂f/∂x dx + ∂f/∂y dy From which follows A = ∂f/∂x B = ∂f/∂y
The idea behind a reverse shock
12 hours ago So in a supernova explosion for example (5th slide) http://www.astro.princeton.edu/~burrows/classes/541/blastwavesChisari.pdf Ambient medium is...
Guass's Law for a charge distribution
12 hours ago First, this is not a homework question, just something I've been confused about for some time. I understand how to use Guass's law in many ways but...
- More from Physics Forums - Classical Physics
More news stories
The news about youth and diabetes keeps getting worse. The latest data from the national TODAY diabetes study shows that children who develop Type 2 diabetes are at high risk to develop heart, kidney and eye problems faster ...
Diabetes May 24, 2013 | not rated yet | 0
(HealthDay)—Type 2 diabetes is more aggressive in children than adults, with signs of serious complications seen just a few years after diagnosis, new research finds.
Diabetes May 23, 2013 | not rated yet | 0
Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a paper published today in BMJ.
Diabetes May 23, 2013 | not rated yet | 0
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
Diabetes May 23, 2013 | not rated yet | 0 |
Widely-used fish oil supplements modestly increase amounts of a hormone that is associated with lower risk of diabetes and heart disease, according to a study accepted for publication in The Endocrine Society's Journal of ...
Diabetes May 22, 2013 | 5 / 5 (2) | 1
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
18 hours ago | 5 / 5 (5) | 5
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
10 hours ago | not rated yet | 1
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
18 hours ago | 5 / 5 (1) | 1
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
18 hours ago | not rated yet | 0
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
18 hours ago | not rated yet | 0